Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Insider David Krempa Sells 16,977 Shares

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 16,977 shares of the business's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $14.92, for a total value of $253,296.84. Following the transaction, the insider now directly owns 629,669 shares in the company, valued at $9,394,661.48. This trade represents a 2.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

David Krempa also recently made the following trade(s):

• On Monday, June 16th, David Krempa sold 10,223 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $14.73, for a total transaction of $150,584.79.
• On Friday, June 13th, David Krempa sold 6,800 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.77, for a total transaction of $100,436.00.

Eton Pharmaceuticals Stock Up 0.7%

Shares of ETON traded up $0.09 during mid-day trading on Thursday, reaching $13.70. The company had a trading volume of 341,413 shares, compared to its average volume of 227,647. Eton Pharmaceuticals, Inc. has a 52 week low of $3.18 and a 52 week high of $21.48. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.43 and a current ratio of 1.97. The company has a market capitalization of $367.43 million, a price-to-earnings ratio of -76.11 and a beta of 1.28. The firm has a 50-day moving average price of $16.63 and a 200 day moving average price of $15.03.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The company had revenue of $17.28 million during the quarter, compared to analysts' expectations of $14.33 million. Eton Pharmaceuticals had a negative return on equity of 3.15% and a negative net margin of 9.49%. On average, sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on ETON shares. B. Riley reiterated a "buy" rating and set a $26.00 target price (up previously from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th. Craig Hallum lifted their price target on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $35.00 price objective (up previously from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th.

Institutional Trading of Eton Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC lifted its stake in shares of Eton Pharmaceuticals by 5.1% in the first quarter. Nantahala Capital Management LLC now owns 1,175,951 shares of the company's stock worth $15,264,000 after buying an additional 57,468 shares in the last quarter. Mink Brook Asset Management LLC purchased a new position in Eton Pharmaceuticals in the 4th quarter worth approximately $6,071,000. Acadian Asset Management LLC lifted its position in Eton Pharmaceuticals by 61.9% in the 1st quarter. Acadian Asset Management LLC now owns 402,428 shares of the company's stock valued at $5,219,000 after acquiring an additional 153,923 shares in the last quarter. Cannell Capital LLC purchased a new stake in Eton Pharmaceuticals during the 4th quarter valued at $5,079,000. Finally, Millennium Management LLC boosted its stake in Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company's stock valued at $4,620,000 after purchasing an additional 217,042 shares during the last quarter. 27.86% of the stock is owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.